Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Benzinga · 1d ago
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.